Efficacy of Osimertinib in Patients With Lung Cancer

Hunan Province Tumor Hospital100 enrolled

Overview

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Advanced Non-Small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must be ≥18 years. * Provision of fully informed consent prior to any study specific procedures. * Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology. * According to the RECIST 1.1 standard, the patient must have at least one measurable lesion. Exclusion Criteria: * None

Locations (1)

Hunan Cancer hospital

Changsha, Hunan, China

RECRUITING

Outcomes

Primary Outcomes

progression-free survival

From registration onto that step until death, or censored at the date of last contact.

Time frame: 3 years

Overall survival

From registration onto that step until death, or censored at the date of last contact.

Time frame: 3 years

Central Contacts

Yongchang C Zhang, MD

CONTACT

+8613873123436 zhangyongchang@csu.edu.cn

Nong Yang, MD

CONTACT

+8613055193557 yangnong0217@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.